HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 66.4%

Neg 0% Neu 0% Pos 66.4%

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.